Medical second opinion market seen reaching $13.49 billion by 2035

The global medical second opinion market is projected to grow from $7.37 billion in 2026 to $13.49 billion by 2035, according to Market Research Future. Demand is being driven by diagnostic error concerns, payer-mandated consults and AI tools that speed specialist matching.

Why it matters: - The market is being shaped by rising demand for diagnostic verification, not discretionary healthcare spending. - Confirmatory consultations can change treatment paths in oncology, neurology and other complex specialties. - Faster specialist matching and payer coverage could make second opinions a routine part of care.

What happened: - Market Research Future projects the global medical second opinion market will rise from $7.37 billion in 2026 to $13.49 billion by 2035. - The forecast implies a 6.95% compound annual growth rate during 2026-2035. - The estimated market base was $6.89 billion in 2025. - The report was released June 25, 2026. - A free sample is available here.

The details: - Rising diagnostic error rates and chronic-disease prevalence are key demand drivers. - A WHO projection cited in the report points to 35 million new annual cancer cases by 2050. - A Johns Hopkins study covering pathology audits from 2013-2023 found oncology misdiagnosis rates between 10% and 20% across developed health systems. - Major U.S. insurers including UnitedHealthcare, Aetna and Cigna now include mandatory or incentivized second-opinion provisions in more than 60% of group-benefit plans. - CMS expanded telehealth-eligible CPT consultative codes in January 2024, adding 14 new codes. - The report says a single second-opinion consultation can prevent more than $50,000 in unnecessary surgeries. - AI-enabled triage platforms are replacing paper referrals and phone-based physician channels. - These platforms can route cases to the most relevant subspecialist in about 30 minutes, versus a traditional 5- to 10-business-day referral cycle. - A customization request is available here. - The full report is available here.

Between the lines: - The market’s growth reflects a shift from optional consultations to embedded care and payer requirements. - Cancer remains the dominant application because treatment decisions are costly and often irreversible. - Online physician portals are gaining share as digital workflows cut turnaround times and lower per-case costs by 25% to 35%. - North America leads today because of payer mandates, academic medical center networks and reimbursement support for virtual consults. - Asia-Pacific is the fastest-growing region as internet-hospital licensing and telemedicine infrastructure expand access to specialist review. - The competitive field is fragmented, with no single company above 10% global revenue share.

What's next: - Market Research Future expects AI-augmented diagnostic workflows to become central to second-opinion management by 2030. - The report says 60% of oncology second-opinion consultations could include AI-generated preliminary assessments by 2030. - Startups have raised more than $800 million in venture funding for oncology decision-support tools since 2023. - Further consolidation is likely as telemedicine platforms and health systems integrate second-opinion services into broader care-navigation offerings.

The bottom line: - Medical second opinions are moving from niche consults to a built-in part of modern diagnosis, and AI is accelerating that shift.